Immix Biopharma (IMMX) Income from Continuing Operations (2021 - 2026)
Immix Biopharma's (IMMX) quarterly Income from Continuing Operations came in at 10086687.0 in Q1 2026, down 122.05% year-on-year from 45744448.93 in Q1 2025, and up 5.62% quarter-over-quarter from 10687830.0 in Q4 2025.
Immix Biopharma (IMMX) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Immix Biopharma has disclosed Income from Continuing Operations across 6 years of filings, most recently posting 10086687.0 for Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 10086687.0, down 122.05% year-over-year; the trailing twelve-month figure through Mar 2026 was 34982772.0 (down 4300.29% YoY), and the FY2025 annual result was 29438613.0, down 1759.03% from the prior year.
- Income from Continuing Operations came in at 10086687.0 for Q1 2026 at Immix Biopharma, up from 10687830.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 15302762.0 in Q4 2024 to a low of 10687830.0 in Q4 2025.
- The 5-year median for Income from Continuing Operations is 4405850.0 (2024), against an average of 3819651.88.
- Across the five-year window, Income from Continuing Operations tumbled 649.04% in 2022 and jumped 396.83% in 2024, its largest moves.
- Immix Biopharma's Income from Continuing Operations stood at 3799837.0 in 2022, then slumped by 35.67% to 5155366.0 in 2023, then surged by 396.83% to 15302762.0 in 2024, then slumped by 169.84% to 10687830.0 in 2025, then increased by 5.62% to 10086687.0 in 2026.
- The last three Income from Continuing Operations figures came in at 10086687.0 (Q1 2026), 10687830.0 (Q4 2025), and 7585692.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Immix Biopharma | 467.59 Mn | 467.59 Mn | - | -10.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.09 Mn |
| Dec 31, 2025 | -10.69 Mn |
| Sep 30, 2025 | -7.59 Mn |
| Jun 30, 2025 | -6.62 Mn |
| Mar 31, 2025 | -4.54 Mn |
| Dec 31, 2024 | 15.30 Mn |
| Sep 30, 2024 | -7.15 Mn |
| Jun 30, 2024 | -4.41 Mn |
| Mar 31, 2024 | -5.33 Mn |
| Dec 31, 2023 | -5.16 Mn |
| Sep 30, 2023 | -4.34 Mn |
| Jun 30, 2023 | -3.60 Mn |
| Mar 31, 2023 | -2.50 Mn |
| Dec 31, 2022 | -3.80 Mn |
| Sep 30, 2022 | -1.54 Mn |
| Jun 30, 2022 | -1.56 Mn |
| Mar 31, 2022 | -1.33 Mn |
| Dec 31, 2021 | -22.76 Mn |
| Sep 30, 2021 | -403,265.00 |
| Jun 30, 2021 | -208,638.00 |